SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests

Kay, Grant Alistair, Owen, Sophie ORCID: https://orcid.org/0000-0002-0458-2357, Giorgi, Emanuele, Clark, David J., Williams, Chris, Menzies, Stefanie ORCID: https://orcid.org/0000-0002-9273-9296, Cuevas, Luis ORCID: https://orcid.org/0000-0002-6581-0587, Davies, Benedict M. O., Eckersley, Nicholas M., Hughes, Grant ORCID: https://orcid.org/0000-0002-7567-7185, Kirwan, Daniela E., Krishna, Sanjeev, Patterson, Ian ORCID: https://orcid.org/0000-0003-3465-0848, Planche, Tim, Staines, Henry M. and Adams, Emily ORCID: https://orcid.org/0000-0002-0816-2835 (2022) 'SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests'. Scientific Reports, Vol 12, Issue 1, e3351.

Preview	Text 41598_2022_Article_7263.pdf - Published Version Available under License Creative Commons Attribution. Download (2MB) | Preview
Preview	Text 41598_2022_7263_MOESM3_ESM.pdf - Supplemental Material Available under License Creative Commons Attribution. Download (144kB) | Preview
Preview	Text 41598_2022_7263_MOESM2_ESM.pdf - Supplemental Material Available under License Creative Commons Attribution. Download (720kB) | Preview

Abstract

Severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread globally since its emergence in 2019. Most SARS-CoV-2 infections generate immune responses leading to rising levels of immunoglobulins (Ig) M, A and G which can be detected using diagnostic tests including enzyme-linked immunosorbent assays (ELISA). Whilst implying previous SARS-CoV-2 infection, the detection of Ig by ELISA does not guarantee the presence of neutralising antibodies (NAb) that can prevent the virus infecting cells. Plaque reduction neutralisation tests (PRNT) detect NAb, but are not amenable to mass testing as they take several days and require use of SARS-CoV-2 in high biocontainment laboratories. We evaluated the ability of IgG and IgM ELISAs targeting SARS-CoV-2 spike subunit 1 receptor binding domain (S1-RBD), and spike subunit 2 (S2) and nucleocapsid protein (NP), at predicting the presence and magnitude of NAb determined by PRNT. IgG S2 + NP ELISA was 96.8% [95% CI 83.8–99.9] sensitive and 88.9% [95% CI 51.8–99.7] specific at predicting the presence of NAbs (PRNT80 > 1:40). IgG and IgM S1-RBD ELISAs correlated with PRNT titre, with higher ELISA results increasing the likelihood of a robust neutralising response. The IgM S1-RBD assay can be used as a rapid, high throughput test to approximate the magnitude of NAb titre.

Item Type:	Article
Subjects:	QU Biochemistry > Enzymes > QU 135 Enzymes QW Microbiology and Immunology > Immune Responses > QW 700 Infection. Mechanisms of infection and resistance. WC Communicable Diseases > Virus Diseases > Viral Respiratory Tract Infections. Respirovirus Infections > WC 506 COVID-19
Faculty: Department:	Biological Sciences > Department of Tropical Disease Biology Biological Sciences > Vector Biology Department Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI):	https://doi.org/10.1038/s41598-022-07263-8
SWORD Depositor:	JISC Pubrouter
Depositing User:	JISC Pubrouter
Date Deposited:	07 Apr 2022 12:04
Last Modified:	15 Jun 2023 13:30
URI:	https://archive.lstmed.ac.uk/id/eprint/20028

Statistics

View details

Actions (login required)

Edit Item